TSOI 8K MERGER IN THE WORK
SECTION 1 – REGISTRANT’S BUSINESS AND OPERATIONS
Item 1.01 Entry into a Material Definitive Agreement
(a)(1) THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (the “Registrant”) entered into a material definitive agreement not made in the ordinary course of its business on December 9 2014. The parties to the agreement are the Registrant and INNOVATIVE SUPPLEMENTS, INC, a California Corporation, (“Innovative”), and ROBERT F. GRAHAM (“Graham”), the sole shareholder and director of Innovative. No material relationship exists between the Registrant and its affiliates on the one hand, and Innovative, its affiliates, or Graham on the other hand.
(a)(2) Upon the terms and subject to the conditions of the Material Definitive Agreement, the Registrant acquired: (i) by assignment, all of Innovative’s contractual right, title and interest in and to proprietary formulations for two nutritional supplement products known under the trade names: (a) “T-Rx”; and, (b) “Vital Female; and, (ii) by purchase, all legal right, title and interest, in and to intellectual property including, but not limited to, Innovative’s nutritional supplement product known under the trade name: “Projuvenol.”
The Material Definitive Agreement provided that in exchange for the assignment of “T-Rx” and “Vital Female,” and the for outright purchase of “Projuvenol,” the Registrant agreed to convey to Innovative and Graham one hundred million (100,000,000) shares of the Registrant’s unregistered restricted common stock valued at par value of $0.001 per share.
